The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Official Title: A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center
Study ID: NCT03117036
Brief Summary: This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Detailed Description: The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows. 1. Registration after informed consent. 2. Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood 3. Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood 4. Regular monitoring disease status and update of survival status 5. Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Samsung Medical Center, Seoul, , Korea, Republic of
Name: Seok Jin Kim, MD, PhD
Affiliation: Samsung Medical Center
Role: PRINCIPAL_INVESTIGATOR